Diabetes Reversal Online Program and Study (DROP Study)
Part of paid clinical trials in Washington D.C., District of Columbia.
- Sponsor
- Physicians Committee for Responsible Medicine
- Study ID
- NCT05572502
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- plant-based diet — BEHAVIORALFor the duration of the study, this arm will: follow a low-fat vegan diet; weigh themselves weekly, and get fasting bloodwork before, during and after the study
Study Details
This is an interventional study that will evaluate the feasibility, implementation, and efficacy of an online, 12-week, plant-based, nutrition education program in a community setting. Data will also be analyzed to see if participation in the program results in reductions glycated hemoglobin levels, body weight, and cholesterol levels.
Key Dates
- Start date
- Sep 21, 2023
- Status verified
- Apr 2024
- Primary completion
- Aug 28, 2024
- Completion
- Dec 31, 2027
Study Design
- Enrollment
- 150 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Vegan dietAll participants will follow a low-fat vegan diet. There are no other study arms or control group.
Primary Outcome Measure
Glycated hemoglobin [ Time Frame: 12 weeks ]
Central Contacts
- VANITA RAHMAN, MD2025277500
- Roxanne Becker, MBChB2022779760
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Physician Committee for Responsible Medicine | Washington D.C. | District of Columbia | 20016 | Shannon Gray, RD (SUB_INVESTIGATOR) James Loomis, MD (SUB_INVESTIGATOR) |
Find similar trials in Washington D.C., DC
By condition
By specialty
Related Studies
- Youth-Onset Type 2 Diabetes and Heart Disease: The Young at Heart Prospective Cohort StudyRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Washington D.C., District of Columbia
- A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)PHASE3 · Recruiting · Eli Lilly and Company · Tucson, Arizona
- Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes PatientsPHASE1/PHASE2 · Not Yet Recruiting · ARKAY Therapeutics · Albany, New York
- The Role of Type 2 Diabetes on Skeletal Muscle Atrophy and Recovery Following Bed Rest in Older AdultsRecruiting · AdventHealth Translational Research Institute · Orlando, Florida